Navigation Links
XBiotech Announces Incorporation Of Its Wholly Owned Subsidiary XBiotech Japan KK
Date:3/26/2013

AUSTIN, Texas, March 26, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced the incorporation of its wholly owned Japanese subsidiary, XBiotech Japan KK. The creation of the Japanese Company is reportedly the first step in XBiotech's strategy to expand its clinical operations and ultimately product reach into the unique Japanese market place.

"XBiotech is committed to availing its drug development technologies to serve unmet medical need in Japan," said Erika Geimonen, Vice President of Business Development, XBiotech. "This is a very special market place and we look forward to working with the PMDA and our Japanese partners to help patients access important therapies. Whether we are talking about our True Human™ antibody therapies, or biosimilars, we offer the possibility of breakthrough with respect to how biological drugs can be used to help sustain Japanese patients and the Japanese healthcare system alike."

XBiotech's production technology is enabling unprecedented cost efficiencies. Making proprietary True Human™ biologics affordable will help enable access to new and larger markets, and promises to set a new bar for drug pricing. Yet, dramatic cost reductions for biosimilar drugs could be game changing—and permit very aggressive competition for market share for existing world-leading biological drug products. Hence, XBiotech has recently expanded its pipeline with the development of biosimilars.

About XBiotech
The Company has developed simple, minimal infrastructure production technology, dramatically reducing capital requirements and lead times, while greatly improving regulatory compliance and production flexibility. These processes are now a cornerstone of XBiotech's commercialization platform. The Company is now equipped with know how and technology to produce the most affordable biological drug products in the world—and to establish a new paradigm for cost efficiency in the biopharmaceutical industry.

At the heart of XBiotech is its pipeline of True Human™ monoclonal antibodies, the first of a new class of better, safer therapeutic antibodies. The use of the Company's lead True Human™ antibody in clinical programs to treat acne, psoriasis, cachexia, cancer, type 2 diabetes and cardiovascular disease have created anticipation for a single therapeutic agent capable of treating multiple diseases by blocking chronic inflammation. XBiotech believes that this extraordinary lead product represents what is perhaps the greatest single-product value potential in the history of therapeutic antibodies.

XBiotech is building on a foundation of groundbreaking therapies, innovation and a commitment to unmet medical needs worldwide. 
www.xbiotech.com.

Contact: 
Investors: 
Erika Geimonen
XBiotech
info@xbiotech.com
512.386.2906 


'/>"/>
SOURCE XBiotech
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. XBiotech Announces Positive Phase II Clinical Trial Results for Lead Candidate MABp1 in Acne Vulgaris
2. XBiotech Expands Portfolio to Include Biosimilars
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Spherix Announces Third Quarter Financial Results
11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):